PTC Therapeutics (NASDAQ:PTCT) VP Sells $171,196.30 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 2,266 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $75.55, for a total value of $171,196.30. Following the transaction, the vice president directly owned 120,901 shares in the company, valued at approximately $9,134,070.55. This represents a 1.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Mark Elliott Boulding also recently made the following trade(s):

• On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $133,816.05.
• On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.44, for a total value of $377,829.76.
• On Monday, November 17th, Mark Elliott Boulding sold 2,812 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.99, for a total value of $213,683.88.

PTC Therapeutics Trading Down 0.5%

Shares of PTCT opened at $76.85 on Friday. The firm has a fifty day moving average price of $76.43 and a 200-day moving average price of $62.53. The firm has a market capitalization of $6.17 billion, a P/E ratio of 8.98 and a beta of 0.49. PTC Therapeutics, Inc. has a 12-month low of $35.95 and a 12-month high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping the consensus estimate of ($1.19) by $1.39. The company had revenue of $211.01 million for the quarter, compared to the consensus estimate of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm’s revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.39) EPS. Analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. boosted its position in PTC Therapeutics by 3.0% during the second quarter. Ameritas Investment Partners Inc. now owns 7,936 shares of the biopharmaceutical company’s stock valued at $388,000 after purchasing an additional 231 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 236 shares during the last quarter. Optiver Holding B.V. boosted its holdings in shares of PTC Therapeutics by 96.5% in the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 249 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of PTC Therapeutics by 42.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 295 shares during the last quarter. Finally, IFP Advisors Inc raised its stake in shares of PTC Therapeutics by 68.1% during the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 310 shares in the last quarter.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent fundamentals still supportive — PTC reported an earnings and revenue beat in its last quarter (Nov.) and maintains strong margins relative to peers, which underpins the stock’s valuation and analyst interest. MarketBeat PTCT profile
• Neutral Sentiment: Small inducement grant: the company approved 300 restricted stock units for a new non‑executive employee on Jan. 2 — immaterial dilution and likely not a major near‑term driver. PR Newswire: Inducement Grants
• Neutral Sentiment: Analyst consensus is a “Hold” with a mixed set of price targets and ratings — this produces limited conviction among buy‑side actors and can temper short‑term moves. Analyst consensus report
• Negative Sentiment: Heavy insider selling disclosed in multiple Form 4s — several executives and directors (including the CEO, CFO, EVP, VPs and others) sold several tens of thousands of shares across Jan. 6–7 at ~\$77 per share, representing millions of dollars of proceeds. Collective insider sales at this scale can put near‑term downward pressure on the stock and signal to some investors that insiders are taking gains. The filings and aggregated alert are here for review. InsiderTrades: Jan. insider sales alert

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Morgan Stanley reissued an “overweight” rating and issued a $90.00 price objective on shares of PTC Therapeutics in a research note on Thursday. Wall Street Zen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Royal Bank Of Canada lowered PTC Therapeutics from an “outperform” rating to a “sector perform” rating and raised their price target for the company from $82.00 to $91.00 in a research note on Monday, December 1st. TD Cowen lifted their price objective on PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, November 5th. Finally, Jefferies Financial Group upped their price objective on shares of PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, October 28th. Nine equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $77.27.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.